NASDAQ:TLIS - Nasdaq - US87424L2079 - Common Stock - Currency: USD
4.38
+0.22 (+5.29%)
The current stock price of TLIS is 4.38 USD. In the past month the price decreased by -50.79%. In the past year, price decreased by -27.24%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Chicago, Illinois and currently employs 99 full-time employees. The company went IPO on 2021-02-12. The firm is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
TALIS BIOMEDICAL CORP
1375 West Fulton Market, Suite 700
Chicago ILLINOIS 94025 US
CEO: Brian Coe
Employees: 99
Company Website: https://talisbio.com/
Phone: 16504333000
The current stock price of TLIS is 4.38 USD. The price increased by 5.29% in the last trading session.
The exchange symbol of TALIS BIOMEDICAL CORP is TLIS and it is listed on the Nasdaq exchange.
TLIS stock is listed on the Nasdaq exchange.
6 analysts have analysed TLIS and the average price target is 5.1 USD. This implies a price increase of 16.44% is expected in the next year compared to the current price of 4.38. Check the TALIS BIOMEDICAL CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TALIS BIOMEDICAL CORP (TLIS) has a market capitalization of 7.97M USD. This makes TLIS a Nano Cap stock.
TALIS BIOMEDICAL CORP (TLIS) currently has 99 employees.
TALIS BIOMEDICAL CORP (TLIS) has a resistance level at 4.52. Check the full technical report for a detailed analysis of TLIS support and resistance levels.
The Revenue of TALIS BIOMEDICAL CORP (TLIS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the TLIS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TLIS does not pay a dividend.
TALIS BIOMEDICAL CORP (TLIS) will report earnings on 2024-11-12, after the market close.
TALIS BIOMEDICAL CORP (TLIS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-31.43).
The outstanding short interest for TALIS BIOMEDICAL CORP (TLIS) is 0.34% of its float. Check the ownership tab for more information on the TLIS short interest.
ChartMill assigns a fundamental rating of 3 / 10 to TLIS. While TLIS has a great health rating, there are worries on its profitability.
Over the last trailing twelve months TLIS reported a non-GAAP Earnings per Share(EPS) of -31.43. The EPS increased by 42.72% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -69.35% | ||
ROE | -100.93% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 37% to TLIS. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 27.62% and a revenue growth -100% for TLIS